We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ABEBF market cap is 0. The company's latest EPS is SEK and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 1.51M | 755k | 1.18M | 1.79M | 2.65M |
| Operating Income | -2.47M | -3.7M | -9.18M | -19.46M | -16.8M |
| Net Income | -2.47M | -3.64M | -9.17M | -19.38M | -16.72M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 4.89M | 2.97M | 31.37M | 19.57M | 9.35M |
| Total Liabilities | 937k | 2.54M | 2.22M | 2.8M | 3.69M |
| Total Equity | 3.95M | 428k | 29.15M | 16.78M | 5.66M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | N/A | -2.75M | -9.68M | -19.69M | -17.71M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | N/A | 1M | 20.73M | 23.17M | 5.6M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 14.46M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Abera Bioscience AB (GM) |
| Address |
svetsarv��gen 15 2 tr solna SE-171 41 |
| Website | https://www.aberabio.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
